C4 Therapeutics Inc. (NASDAQ:CCCC) Relative Strength Index (RSI) is 58.32, with weekly volatility at 4.98% and ATR at 2.43. The CCCC stock’s 52-week price range has touched low of $22.40 and a $48.97 high. Intraday shares traded counted 0.49 million, which was -37.65% lower than its 30-day average trading volume of 358.27K. Its shares traded higher over the last trading session, gaining 0.34% on 06/03/21. The shares fell to a low of $37.51 before closing at $38.15. CCCC’s previous close was $38.02 while the outstanding shares total 43.09M.
Investors have identified the Biotechnology company C4 Therapeutics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $1.66 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
C4 Therapeutics Inc. (CCCC) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 322.01 million total, with 37.65 million as their total liabilities.
CCCC were able to record -25.36 million as free cash flow during the 09/01/2021 quarter of the year, this saw their quarterly net cash flow reduce by -86.81 million. In cash movements, the company had a total of -24.93 million as operating cash flow.
Potential earnings growth for C4 Therapeutics Inc. (CCCC)
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 7.43 million trying to sell their products during the last quarter, with the result yielding a gross income of 27.93 million. This allows shareholders to hold on to 43.09M with the recently reported earning now reading -0.49 cents per share. This is a figure that compared to analyst’s prediction for their 09/01/2021 (-0.49 cents a share).
Having a look at the company’s valuation, the company is expected to record -1.99 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on CCCC sounds very interesting.
Is the stock of CCCC attractive?
In related news, Director, Salter Malcolm sold 755 shares of the company’s stock in a transaction that recorded on May 21. The sale was performed at an average price of 37.12, for a total value of 28,026. As the sale deal closes, the Chief Medical Officer, Crystal Adam now sold 15,000 shares of the company’s stock, valued at 566,536. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.50%.
4 out of 4 analysts covering the stock have rated it a Buy, while 0 have maintained a Hold recommendation on C4 Therapeutics Inc.. 0 analysts has assigned a Sell rating on the CCCC stock. The 12-month mean consensus price target for the company’s shares has been set at $56.50.